---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-039529"
form_type: "8-K"
ticker: "OSTX"
cik: "0001795091"
company_name: "OS Therapies Inc"
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:52:01.122848+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# OS Therapies completes $5.25M registered direct offering, expects $4M non-dilutive funds from UK subsidiary

## Summary
- Gross proceeds $5.25M; net proceeds ~$4.7M from offering of 2.5M shares (or pre-funded warrants) and 3.8M common warrants at $1.40/share.
- Expects ~$2M VAT refunds from UK sub. in Q2 2026 and ~$2M R&D tax credits in H2 2026.
- Combined funding expected to extend cash runway into 2027.
- Targets OST-HER2 regulatory approvals (US FDA, UK MHRA, EU EMA) in H2 2026.
- 90-day lockup on further equity issuance; Ceros received 7% fee and warrants at $1.54.

## SEC filing metadata
- accession: 0001213900-26-039529
- form_type: 8-K
- ticker: OSTX
- cik: 0001795091
- company_name: OS Therapies Inc
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1795091/000121390026039529/0001213900-26-039529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1795091/000121390026039529/ea0284488-8k_ostherapies.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-039529
- JSON: https://secwatch.observer/filing/0001213900-26-039529.json
- Plain text: https://secwatch.observer/filing/0001213900-26-039529.txt

## Source-grounded claims
- claim_id: a19c91e66bdf8ff3fdbaa9e9a064dedb3e420ccf
  claim: OS Therapies Inc entered into Purchase Agreement with purchasers identified on the signature pages thereto (effective 2026-03-31).
  evidence_excerpt: On March 31, 2026, OS Therapies Incorporated (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers identified on the signature pages thereto (the “Purchasers”), pursuant to which the Company offered for sale to the Purchasers in a registered direct offering (the “Offering”) an aggregate of 2,505,073 shares of its common stock and, in lieu thereof, pre-funded warrants to purchase up to 1,250,893 shares of its common stock (the “pre-funded warrants”), and accompanying warrants to purchase up to 3,755,966 shares of its common stock (the “common warrants”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1795091/000121390026039529/0001213900-26-039529-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.